SynapCell
- Company typePrivate
- Founded2004
- HeadquartersGrenoble, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
SynapCell firmographics
Firmographics- Name
- SynapCell
- Legal name
- SynapCell
- Website
- https://synapcell.fr
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where SynapCell is headquartered
LocationHeadquarters
- HQ city
- Grenoble
- HQ country
- France
- HQ region
- Europe
Markets served
SynapCell business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Preclinical Contract Research Services: Fee-for-service contract research organization providing preclinical EEG testing services to pharmaceutical and biotech companies. Revenue is generated through project-based contracts for drug efficacy testing, pharmaco-EEG studies, de-risking studies, and model exploration. Services are tailored to client-specific protocols and compound profiles.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Project-Based Pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels9 records
SynapCell product offering
Product offeringCore offering
SynapCell is a preclinical Contract Research Organization providing EEG-based CNS drug discovery services for pharmaceutical and biotechnology companies. Its core deliverable is the CUE® translational in vivo EEG platform, applied through customized rodent-model studies and EEG biomarker analysis to predict in-human efficacy of drug candidates for epilepsy, movement disorders, psychiatric conditions, and rare diseases.
Product overview
SynapCell is a preclinical Contract Research Organization (CRO) specializing in EEG services for CNS drug discovery. The company operates a platform-plus-services model centered on CUE®, their proprietary translational in vivo EEG platform. Services include Drug Efficacy Testing, Pharmaco-EEG, Sleep & Vigilance States, Model Exploration, De-risking, Collaborative Projects, and Remote Preclinical EEG Laboratory services. The company focuses on select therapeutic areas: Epilepsy (Focal, Absence, Focal-to-Generalized), Movement Disorders (Parkinson's Disease, Essential Tremor), Rare Disorders (Autism, Tauopathy), and Psychiatric Disorders (Schizophrenia, Anxiety and Agitation).
Differentiator
Problem solved
Functional benefit
Brands
- Cue®: SynapCell's translational and predictive in vivo EEG platform designed to predict in-human efficacy of drug candidates during preclinical steps. Cue® combines know-how, expertise, and scientific excellence in brain surgery and EEG signal recording, processing, and analysis.
Products and services
- CUE® Platform SynapCell's translational and predictive in vivo EEG platform that processes preclinical rodent models and their associated EEG biomarkers to predict in-human efficacy of drug candidates during preclinical stages. Used by pharmaceutical and biotechnology companies for CNS drug discovery decision-making.
- Drug Efficacy Testing Preclinical assay service for testing drug efficacy in rodent models targeting CNS disorders including epilepsy, movement disorders, psychiatric conditions, and rare diseases. Provided to pharma and biotech clients as a customized study engagement.
- Pharmaco-EEG Preclinical EEG service for assessing the pharmacodynamic effects of compounds on brain electrical activity. Used by pharma and biotech teams evaluating CNS drug candidates.
- Sleep & Vigilance States Preclinical EEG capability for characterizing compound effects through information on sleep and wakefulness states, providing additional insights beyond standard efficacy testing. Aimed at pharma and biotech teams seeking differentiated CNS compound characterization.
- Model Exploration Service for exploring and validating preclinical rodent models for CNS drug discovery, helping clients identify the most appropriate disease model for their compound.
- De-risking Risk assessment service for preclinical CNS drug development programs, helping clients reduce the risk of late-stage clinical failure by validating efficacy and translatability early.
- Collaborative Projects Co-development partnership model where SynapCell collaborates with clients on neuroscience research projects, acting as an extension of the client's research team from conceptualization to conclusion.
- Remote Preclinical EEG Laboratory Outsourced preclinical EEG laboratory service providing facilities, expertise, translational rodent models, and EEG biomarkers without in-house investment requirements. Functions as a long-term partner familiar with the client's protocols and constraints.
Quantifiable outcome
- Predictive preclinical-to-human translation of drug efficacy for CNS compounds
- +1 more outcomes
Companies that use SynapCell
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles3 records
SynapCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
SynapCell partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- University of UtahcoreCelebration of the 10-year anniversary of collaboration on anti-seizure medications. The partnership has focused on joint research and development efforts for anti-seizure medications, demonstrating a sustained academic-industry collaboration that has produced scientific publications and advanced epilepsy drug discovery.
- Client Research TeamscoreSynapCell positions itself as a collaborative partner rather than a transactional vendor, functioning as an extension of client research teams. The company co-develops projects with clients, providing end-to-end support from conceptualization through conclusion, translating raw EEG data into actionable insights.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
SynapCell competitors and assessment
Company assessmentDirect peers
- PsychoGenics: US-based preclinical CRO with deep CNS expertise including EEG/electrophysiology and translational biomarker discovery. Direct peer in offering specialized in vivo CNS services to pharma with proprietary platforms and rodent disease models.
- Brains On-Line: Netherlands-based preclinical CRO focused on in vivo EEG and CNS pharmacology in rodent models. Highly comparable as a specialized EEG CRO serving pharma CNS drug discovery, though with a different geographic footprint.
- Porsolt: French-headquartered preclinical CRO specializing in CNS and behavioral pharmacology models. Highly comparable to SynapCell in geography, customer base (pharma/biotech CNS programs), and contract research services model, though Porsolt's core is behavioral rather than EEG-based.
Broad incumbents
- WuXi AppTec: Global CRO/CDMO with growing preclinical CNS and translational services capacity. Represents the scale-incumbent competitive threat, particularly for clients seeking integrated discovery-to-development partners.
- Inotiv: US-based preclinical CRO offering discovery, safety assessment, and research models including CNS programs. Comparable as a broad preclinical competitor addressing similar pharma buyers across multiple modalities.
- Labcorp Drug Development: Global CRO offering preclinical and clinical CNS services through its drug development business. Comparable as a full-service incumbent competing for the same pharma outsourcing RFPs SynapCell targets.
- Charles River Laboratories: Global preclinical CRO with extensive CNS capabilities including EEG and translational biomarker services. Competes for the same pharma outsourcing budgets as SynapCell but as part of a much broader discovery and safety portfolio.
- Eurofins Discovery: Large discovery services arm of Eurofins offering preclinical pharmacology including CNS indications. Represents the broad incumbent alternative for pharma sponsors comparing specialist CROs against full-service providers.
Emerging players
- Bionova Scientific: US-based preclinical CRO expanding into biologics and complex therapeutics testing. Adjacent competitor for early-stage biotech preclinical outsourcing budgets where CNS and specialty pharmacology buyers overlap.
- Crown Bioscience: JSR-owned preclinical CRO with translational oncology and CNS disease models. Comparable as a growing specialty CRO targeting translational drug discovery outsourcing budgets with proprietary platform offerings.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
SynapCell social profiles
Digital presenceSynapCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynapCell leadership team
Management profileNumber of profiles
Profiles4 records
SynapCell funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynapCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynapCell
What does SynapCell do?
SynapCell is a preclinical Contract Research Organization providing EEG-based CNS drug discovery services for pharmaceutical and biotechnology companies. Its core deliverable is the CUE® translational in vivo EEG platform, applied through customized rodent-model studies and EEG biomarker analysis to predict in-human efficacy of drug candidates for epilepsy, movement disorders, psychiatric conditions, and rare diseases.
When was SynapCell founded?
SynapCell was founded in 2004. It employs 11 to 50 people.
Where is SynapCell based?
SynapCell is headquartered in Grenoble, France, in the Europe region.
How does SynapCell make money?
One revenue line is on record: preclinical Contract Research Services.
Who are SynapCell's main competitors?
Direct peers on record are PsychoGenics, Brains On-Line and Porsolt. Broad incumbents are WuXi AppTec, Inotiv, Labcorp Drug Development, Charles River Laboratories and Eurofins Discovery. Emerging players are Bionova Scientific and Crown Bioscience.
Does SynapCell have an API?
No public API is recorded for SynapCell.